Commonly-prescribed drugs may influence the onset and progression of Alzheimer's disease

Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One.

Led by Giulio Maria Pasinetti, MD, PhD, the Saunders Family Chair and Professor in Neurology at Mount Sinai, a research team used a to screen 1,600 commercially-available medications to assess their impact on the brain accumulation of beta-amyloid, a protein abnormally accumulated in the brain of Alzheimer's disease and implicated in . They found that currently-available medications prescribed for conditions such as hypertension, depression, and insomnia were found to either to block or to enhance the accumulation of beta-amyloid, the component of .

"This line of investigation will soon lead to the identification of common medications that might potentially trigger conditions associated with the prevention, or conversely the onset, of Alzheimer's disease," said Dr. Pasinetti. "They may be a novel reference for physicians to consider when prescribing the most appropriate drug, particularly in subjects at high risk for Alzheimer's disease."

To validate the screening protocol, Dr. Pasinetti and his colleagues administered these drugs in mice that were genetically engineered to develop the hallmark amyloid plaques associated with Alzheimer's disease. After six months of treatment with blood pressure medicines, amyloid plaques and neurodegeneration were significantly reduced in the mice. One such medicine was Carvedilol, now under in Alzheimer 's disease with the intent to slow down memory deterioration.

"In recent years, amyloid plaques have become one of the main focal points in the search to understand and to treat Alzheimer's disease," said Dr. Pasinetti. "Thus, identifying treatments that prevent harmful beta-amyloid generation will help in the development of treatments for Alzheimer's disease. For example, one very exciting finding of our study is that , already approved for treatment of hypertension, may immediately become a promising drug for the treatment of Alzheimer's as well."

The authors discuss the limitations of the research, noting that studies must be immediately verified in human-safety studies that examine the effects of the drugs independent of the original indication. Dr. Pasinetti hopes these findings will lead to multiple clinical trials in the future to identify preventive drugs, which will need to be prescribed at tolerable dosages.

"If we can repurpose drugs currently used for different indications, such as lowering blood pressure, this could have dramatic implications for this population," said Dr. Pasinetti.

add to favorites email to friend print save as pdf

Related Stories

Alzheimer's brain change measured in humans

Jun 12, 2013

Scientists at Washington University School of Medicine in St. Louis have measured a significant and potentially pivotal difference between the brains of patients with an inherited form of Alzheimer's disease ...

Carmustine decreases amyloid beta plaques

Mar 25, 2013

Long term treatment by carmustine, a chemical relative of mustard gas and already used to treat some types of brain cancer, can decrease the amount of amyloid β and number of amyloid plaques in a mouse model of Alzheimer's ...

A new strategy required in the search for Alzheimer's drugs?

May 24, 2013

In the search for medication against Alzheimer's disease, scientists have focused – among other factors – on drugs that can break down Amyloid beta (A-beta). After all, it is the accumulation of A-beta that causes the ...

Recommended for you

Comprehensive report on dementia guides social care

15 hours ago

The most comprehensive report yet into dementia care in the North East has been published by the Northern Rock Foundation, with help from Newcastle University academics. The report Dementia 2014: a North East Perspective coinc ...

Researchers identify potential biomarker for AD

Jul 28, 2014

Researchers from Boston University School of Medicine (BUSM) report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead ...

User comments